A Phase I Trial and PK Study of Cediranib (AZD2171), an Orally Bioavailable Pan-Vegfr Inhibitor, in Children With Recurrent or Refractory Primary CNS Tumors
Child's Nervous System - Germany
doi 10.1007/s00381-015-2812-5
Full Text
Open PDFAbstract
Available in full text
Date
July 19, 2015
Authors
Publisher
Springer Science and Business Media LLC